SG11202002563WA - Long-acting conjugates of glp-2 derivatives - Google Patents

Long-acting conjugates of glp-2 derivatives

Info

Publication number
SG11202002563WA
SG11202002563WA SG11202002563WA SG11202002563WA SG11202002563WA SG 11202002563W A SG11202002563W A SG 11202002563WA SG 11202002563W A SG11202002563W A SG 11202002563WA SG 11202002563W A SG11202002563W A SG 11202002563WA SG 11202002563W A SG11202002563W A SG 11202002563WA
Authority
SG
Singapore
Prior art keywords
glp
derivatives
long
acting conjugates
conjugates
Prior art date
Application number
SG11202002563WA
Other languages
English (en)
Inventor
Jaehyuk Choi
Min Young Kim
In Young Choi
Sung Youb Jung
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of SG11202002563WA publication Critical patent/SG11202002563WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202002563WA 2017-09-28 2018-09-28 Long-acting conjugates of glp-2 derivatives SG11202002563WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170126577 2017-09-28
PCT/KR2018/011586 WO2019066586A1 (ko) 2017-09-28 2018-09-28 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체

Publications (1)

Publication Number Publication Date
SG11202002563WA true SG11202002563WA (en) 2020-04-29

Family

ID=65902619

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002563WA SG11202002563WA (en) 2017-09-28 2018-09-28 Long-acting conjugates of glp-2 derivatives

Country Status (16)

Country Link
US (3) US11530249B2 (zh)
EP (1) EP3689898A4 (zh)
JP (2) JP2020534840A (zh)
CN (1) CN111433221A (zh)
AR (1) AR113258A1 (zh)
AU (1) AU2018339210B2 (zh)
BR (1) BR112020006189A2 (zh)
CA (1) CA3084326A1 (zh)
EA (1) EA202090571A1 (zh)
IL (1) IL273528A (zh)
MX (1) MX2020004453A (zh)
PH (1) PH12020550105A1 (zh)
SG (1) SG11202002563WA (zh)
TW (2) TWI795443B (zh)
WO (1) WO2019066586A1 (zh)
ZA (1) ZA202001888B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210082120A (ko) * 2019-12-24 2021-07-02 한미약품 주식회사 Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물
WO2021198195A1 (en) 2020-03-30 2021-10-07 Zealand Pharma A/S Agonist combination
KR20210124071A (ko) * 2020-04-03 2021-10-14 한미약품 주식회사 Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물
IL298964A (en) 2020-06-09 2023-02-01 Vectivbio Ag Manufacture, formulation and dosage of APRAGLUTIDE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
AU2002233089B2 (en) * 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
US20090238838A1 (en) * 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
CN1956998B (zh) * 2004-04-23 2012-12-12 康久有限责任公司 用于纯化白蛋白结合物的方法
KR101200227B1 (ko) * 2005-05-04 2012-11-13 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
KR101746686B1 (ko) * 2010-10-26 2017-06-15 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―２（ｇｌｐ―２）약물 결합체
JP6206972B2 (ja) * 2011-09-12 2017-10-04 アムニクス オペレーティング インコーポレイテッド グルカゴン様ペプチド−２組成物およびその作製法および使用法
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체

Also Published As

Publication number Publication date
US11530249B2 (en) 2022-12-20
US20200262888A1 (en) 2020-08-20
TW201927806A (zh) 2019-07-16
US20230090790A1 (en) 2023-03-23
EP3689898A1 (en) 2020-08-05
EP3689898A4 (en) 2021-06-16
JP2023138505A (ja) 2023-10-02
TWI794897B (zh) 2023-03-01
EA202090571A1 (ru) 2020-07-30
US20220251164A1 (en) 2022-08-11
AU2018339210B2 (en) 2023-02-02
IL273528A (en) 2020-05-31
MX2020004453A (es) 2020-07-24
KR20190037181A (ko) 2019-04-05
TW202142560A (zh) 2021-11-16
AR113258A1 (es) 2020-03-11
CN111433221A (zh) 2020-07-17
WO2019066586A1 (ko) 2019-04-04
KR20240013836A (ko) 2024-01-30
AU2018339210A1 (en) 2020-04-16
TWI795443B (zh) 2023-03-11
ZA202001888B (en) 2021-05-26
CA3084326A1 (en) 2019-04-04
PH12020550105A1 (en) 2020-12-07
JP2020534840A (ja) 2020-12-03
BR112020006189A2 (pt) 2020-10-13

Similar Documents

Publication Publication Date Title
IL291291A (en) A glucagon derivative and a preparation containing its long-term active conjugate
SI3592393T1 (sl) Sprostljivi konjugati
ZA201607385B (en) Anti-ptk7 antibody-drug conjugates
IL248221B (en) Antibody-drug conjugates with high drug loading
ZA201700306B (en) Her2 antibody-drug conjugates
EP3204018A4 (en) Neoadjuvant use of antibody-drug conjugates
ZA201707475B (en) Compositions comprising antibody-duocarmycin drug conjugates
IL273528A (en) Long-term conjugates of GLP-2 derivatives
GB201702031D0 (en) Pyrrolobenzodiazepine-antibody conjugates
ZA202000215B (en) Long-acting formulations
HK1257352A1 (zh) 靶向gcc的抗體-藥物綴合物
EP3538098A4 (en) ANTIBODY-ACTIVE SUBSTANCE CONJUGATES
EP3463424A4 (en) Glucagon-Like Peptide-1 T3 CONJUGATES
GB201719391D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201706466D0 (en) pyrrolobenzodiazepine-peptide conjugates
GB201702029D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201418984D0 (en) Novel drug conjugates